WuXi AppTec Reports Solid First-Quarter 2020 Results
SHANGHAI, April 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and del...
WuXi AppTec Reports Strong 2019 Annual Results
Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year toRMB2,407 Million Adjusted Diluted Non-IFRS EPS Up by 19.7% to RMB1.46[1] SHANGHAI, March 24, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. ...
WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform
PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully ...
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility
SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- STA Pharmaceutical Co., Ltd.,
WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies
SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec. Th...
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...
WuXi AppTec Reports First Half 2019 Interim Results
* Revenue Accelerated 33.7% Year-Over-Year to RMB 5,894 Million * Gross Profit Up 30.0% Year-Over-Year to RMB 2,284 million[1] * Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year toRMB 1,179 Million * Small Molecule CDMO/CMO Pipeline has Grown to 800...
WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections
SHANGHAI, July 23, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) inShanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two...
WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies
SHANGHAI, June 29, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its ded...
WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development
SHANGHAI and SAN DIEGO, May 5, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired Pharmapace, Inc., a US-based clinical research services company with expertise of provid...
WuXi AppTec Reports Strong 2018 Annual Results
SHANGHAI, March 22, 2019 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its audited annual results for the year endedDecember 31, ...
WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange
HONG KONG and SHANGHAI, Dec. 13, 2018 /PRNewswire/ -- WuXi AppTec Co., Ltd. ("WuXi AppTec" or "the Company"; Stock code: 603259.SH/2359.HK) today announced the listing of approximately 116 million H-shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price ofHK$68 per sha...
WuXi AppTec Opens Its New Medical Device Testing Center in Suzhou
SUZHOU, China, Nov. 16, 2018 /PRNewswire/ -- WuXi AppTec announces today that its Laboratory Testing Division's new Medical Device Testing Center opens today in Suzhou,China. This marks the full implementation of WuXi AppTec's medical device testing capabilities in the Chinese market, which works...
WuXi AppTec and Insilico Medicine Link Next-Generation Artificial Intelligence and Drug Discovery
WuXi AppTec and Insilico Medicine establish a close strategic collaboration to integrate next-generation artificial intelligence with drug discovery BALTIMORE, Maryland and SHANGHAI, June 12, 2018 /PRNewswire/ -- Insilico Medicine, aBaltimore-based next-generation artificial intelligence company ...
WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock Exchange
SHANGHAI, May 7, 2018 /PRNewswire/ -- WuXi AppTec Co., Ltd. ("WuXi AppTec" or "the Company"; Stock Code: 603259), a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced listing of its initial public offering of 104,198,600 shar...
